Background -Insect bite hypersensitivity (IBH) is an allergic dermatitis of horses caused by bites of Culicoides spp. IBH does not occur in Iceland because of the absence of Culicoides, but the prevalence is high in horses imported from Iceland to environments where Culicoides are present.
Introduction
Insect bite hypersensitivity (IBH) is an allergic, pruritic dermatitis of horses caused mainly by immunoglobulin (Ig)E-mediated reactions to bites of insects of the genus Culicoides (midges), affecting 5-50% of horses, depending on the horse breed, family and environment. 1 During summer, when the insects are present in the environment, horses with IBH suffer from severe pruritic dermatosis affecting the mane and the tail area, and sometimes also the ventral midline and the face. Absence of the insects in winter leads to temporary remission. The causative allergens for IBH, salivary gland proteins from Culicoides, have been characterized at the molecular level and produced as recombinant proteins. [2] [3] [4] [5] [6] These recombinant allergens (r-allergens) bind serum IgE from IBH-affected animals, but only rarely from healthy control horses. [3] [4] [5] [6] [7] Affected horses have been shown to react to antigens of many different indigenous, as well as nonindigenous Culicoides spp. in intradermal tests, 8, 9 therefore suggesting shared common allergens between species. 10 In mainland Europe, midges from the Culicoides obsoletus (C. obsoletus) complex are the most common species; 11 however, IBH-affected horses have serum IgE antibodies binding to various salivary gland proteins from laboratory-bred C. nubeculosus.
Nevertheless, studies suggest that allergens derived from C. obsoletus, the most frequent Culicoides spp. found in the environment of horses, are more immunereactive for IBH than those from laboratory-bred, nonindigenous species. 5, 6 However, not all allergens from C. obsoletus corresponding to previously described C. nubeculosus allergens have been identified.
Insect bite hypersensitivity does not occur in horses born and living in Iceland due to the lack of antigen exposure because Culicoides spp. are absent. After importation of horses born in Iceland to continental Europe, where Culicoides spp. are present, ≥50% of the imported horses develop IBH when exposed to Culicoides. Conversely, the prevalence of IBH in Icelandic horses born in Europe, and thus exposed to Culicoides already as foals, is at the same level as in other breeds (3-10%). 1 Even though first exposure to Culicoides spp. at an adult age was found to be the main risk factor for developing IBH in exported Icelandic horses, 13 the exact reasons for the high prevalence of IBH in these horses are still subject to speculation. Although previous studies had demonstrated that IBH-affected horses of the Icelandic breed often have high IgE levels against one or more recombinant C. nubeculosus allergens, 4 the time point and possible predictive value of the initial increase in allergen-specific serum IgE are unknown.
The aims of the study were to determine the IgE response pattern of horses imported from Iceland to Europe in a longitudinal study and to test whether -out of a panel of recombinant allergens -a first sensitizing allergen can be identified. Then, in the next part of the study, allergens that seemed to be the most relevant were selected and the IgG subclass response measured in order to determine which IgG subclasses are associated with IBH and whether allergen-specific IgE or IgG antibodies can possibly be used as predictor for the development of IBH.
Material and methods

Horses
Thirty two horses with a well-defined clinical diagnosis regarding occurrence of IBH (16 horses with and 16 horses without IBH) were selected out of a group of Icelandic horses born in Iceland and imported to Europe and monitored over a period of 3-5 years following import. 14 The mean age at time of import of the 32 horses was 7.7 years (range 6-11 years). At time of import the horses had no signs of pruritus. Following importation, the horses (20 geldings, 12 mares) lived in different stables throughout Switzerland, where Culicoides were known to be present, based on the presence of at least one IBH-affected individual in each of the stables. The horses were examined clinically over a period of four to five years, at the time of import and then every year in autumn, at the end of the Culicoides season. The clinical history was assessed; to be assigned to the IBHaffected group the typical clinical signs of IBH had to recur the following summer, after a remission period in winter. After clinical signs became apparent, nearly all affected horses were treated by insect avoidance through covering with blankets and stabling, as well as local application of various lotions for insect and pruritus control. The horses assigned to the healthy outcome (H) group had no history of skin problems during the four year period of observation and no preventive measures such as blankets in summer were taken. The power of the study to detect differences in mean antibody levels between horses in the IBH and H group was evaluated with the software WinEpiscope 2.0 (Epidecon, Wageningen University, NL). The available sample size of 16 horses per group was sufficient to detect a difference between means of 1.1 times the standard deviation with a power of 80%, and a significance level of 5%.
Blood samples
Blood samples were obtained before first exposure to Culicoides allergens and after exposure at the end of each subsequent Culicoides season. Blood was collected from the jugular vein using Serum Clot Activator-containing vacutainers (Vacuette â ; Greiner BioOne, St. Gallen, Switzerland). Serum was separated and stored at À80°C until used. The study was approved by the Animal Experimental Committee of the Canton of Berne, Switzerland (No. BE 121/05 and BE 51/13).
Allergens and antigens
Ten recombinant C. nubeculosus salivary gland allergens (rCul n 1-rCul n 10) 3, 4 and three recombinant C. obsoletus salivary gland allergens rCul o 1, 5 rCul o 2 5 and rCul o 3, 6 were used in the study. They were all expressed in Escherichia coli and purified, as described previously. 4 Additionally, rCul o 3 was expressed in insect cells (Bac-rCul o 3) and used for comparison. Briefly, rCul o 3 was expressed in insect cells with the Bac-to-Bac Baculovirus expression system (Invitrogen, Waltham, MA, USA, https://www.thermofisher.com) as a SUMOstar fusion protein (Life Sensors, Malvern, PA, USA, https://www.lifesen sors.com) in accordance with manufacturers' protocol. The baculovirus was amplified in Sf-9 insect cells and the protein expressed in High five insect cells. The protein was purified under denaturing conditions with the HIS-select TM nickel affinity gel (Sigma, St. Louis, MO, USA, https://www.sigmaaldrich.com) according to protocol and dialysed against 4 M urea. After dialysis, Bac-rCul o 3 was analysed with SDS-PAGE and the gel stained with Coomassie blue, (PhastGel Blue R, Sigma) using standard protocols ( Figure S1 ) or transferred to a PVDF membrane (Millipore, Hellerup, Denmark, http://www.merck millipore.com) and detected with mouse anti-His antibody (Bio-Rad, Hercules, CA, USA, https://www.bio-rad-antibodies.com), diluted 1:1,000, followed by the standard procedure of Western blot, as described previously. 15 Thorax extract from C. nubeculosus (NubTE) and whole body extract from C. obsoletus complex midges (ObsWBE) were prepared as described previously. 5 Equine Influenza A Fontainebleau 79 inactivated virus (APHA, Weybridge, Surrey, UK; EURL Influenzavirus), was used as a control antigen in the IgG-subclasses enzyme-linked immunosorbent assay (ELISA), because Icelandic horses are not vaccinated against equine Influenza in Iceland, whereas they are vaccinated following import into Switzerland.
IgE and IgG subclasses enzyme-linked immunosorbent assay
Allergen-specific serum IgE levels against the ten recombinant C. nubeculosus allergens and NubTE, as well as against the three C. obsoletus r-allergens and ObsWBE were determined by indirect ELISA. Levels of serum IgG subclasses against three of the most relevant rCulicoides allergen, rCul n 4, rCul o 1, rCul o 3, and NubTE and equine Influenza, were determined by ELISA, as described previously. 15 Briefly, microtitre plates were coated with 2 lg/mL allergens, followed by blocking with blocking buffer (Phosphate buffered saline containing 5% dry milk powder and 5% Tween-20). All dilutions of serum samples and antibodies were made in blocking buffer. Following washing, test serum samples were added in duplicates to the plates at a dilution of 1:5 for IgE and 1:100 for IgG subclasses and incubated at 4°C overnight. After washing, monoclonal antibodies specific for equine IgE (1 lg/mL, clone 3H10) 16 or for equine IgG1 (1 lg/mL, CVS45), IgG1/3 (1 lg/mL clone 159), 17 IgG4/7 (1 lg/mL; CVS 39) and IgG5
(1 lg/mL; clone 416) 17 were added and incubated for 2 h at room temperature on a shaker. After washing, alkaline phosphatase conjugated, affinity purified goat anti-mouse IgG (Jackson Immuno Research; Newmarket, UK) was added and the plates developed using phosphatase substrate (Sigma) in 10% diethanolamine (Sigma), pH 9. (Figure 1) . In order to further analyse IgE reactivity to the single allergens, an arbitrary cut-off value was used to distinguish between positive and negative reactions in the allergen-specific IgE ELISA. The cut-off was defined as the mean plus two standard deviation values of the ELISA values from all horses at time T0, before exposure to Culicoides.
Enzyme-linked immunosorbent assay results of the IgG subclasses were shown as OD 405 values after a blank correction on the optical density and correction between plates, as described previously. 5 
Statistical analyses
Statistical analyses were carried out using the software programme NCSS 10 (NCSS; Kaysville, UT, USA). Descriptive statistics were run on the IgE and IgG data, and Shapiro-Wilk W test showed that the data were not normally distributed.
In order to assess factors influencing the antibody response, data were analysed by function of the clinical end-point, namely horses that remained healthy until the fourth summer after import (H group) or developed IBH at any time point within this time period (IBH group), and by function of time. Time point T0 corresponded to the first blood sample taken before exposure to Culicoides midges. T1, T2 and T3 represented the times of blood withdrawals and clinical examination at the end of each subsequent summer, following exposure to Culicoides. In this analysis, the horses were grouped according to the clinical end-point only and not to the diagnosis at the actual time point.
In order to assess effects of the clinical end-point (IBH or H) in function of time (summer after import, T0-T3) and potential interactions thereof on allergen-specific IgE and IgG subclasses, a repeated measures ANOVA was performed ( Table 1 ). The Shapiro-Wilk W test showed that after log-transformation of the data, there was no severe violation of normality (Shapiro-Wilk W ≥ 0.96) for the Sum (IgECul n) and Sum (IgECul o) and for IgG1, IgG1/3, IgG4/7, IgG5 and IgE antibody levels to rCul n 4, NubTE, rCul o 1, rCul o 3, Bac-Cul o 3 and influenza, whereas the distribution of the remaining antibody levels remained non-normal after log transformation and repeated measures ANOVA could thus not be performed. Separate models were run for each antigen, with levels of IgG1, IgG1/3, IgG4/7, IgG5 and IgE as outcome variables, respectively. Interaction of time (=summer after import) and clinical end-point was included in the models. Mauchly's test was used to check for the assumption of circularity of within-subject covariance matrices. Because this assumption was not always fulfilled, the Geisser-Greenhouse correction was used for the within-subject F test. For significant factors in any of the repeated measures ANOVA models, significant subgroup differences were identified correcting for multiple testing with the Tukey-Kramer method (Table 1 ). Fisher's exact test was used to compare the proportion of end-point IBH and end-point H horses with IgE levels above cut-off (=positive) to the single allergens at T0, T1, T2 and T3 (Table S1 ).
In order to further investigate IgE reactivity to the various Culicoides allergens at the time of first clinical signs of IBH, serum antibody levels were compared between end-point IBH horses at the time of onset of clinical signs (T IBH ) and end-point H horses matched for the corresponding time points. To investigate changes in Figure 1 . Comparison of the sum of allergen-specific serum immunoglobulin (Ig)E levels against rCul n 1-10 (a) and rCul o 1-3 (b), respectively, between the end-point insect bite hypersensitivity (IBH) (shaded box) and the end-point healthy (H) (white box) horse groups at time points T0-T3. Results are shown as log of sum IgE Cul n 1-10 (a) and log sum IgE Cul o 1-3 (b) in Relative ELISA Units (REU). T0-T3 correspond to the yearly blood samples, with T0 representing the blood sample collected before exposure to Culicoides and T1-T3 representing the blood samples collected at the end of each subsequent summer. Within the horse group that developed IBH during the follow-up study (=end-point IBH group) the cumulative percentages of horses with IBH at each time point were 0% at T0, 25% at T1, 69% at T2 and 88% at T3. The last two horses (12%) developed IBH at T4. IgE levels are not shown for this time point because too many horses had to be withdrawn from the study at T4 because of treatment with corticosteroids. A repeated measures ANOVA was performed. Asterisks indicate significant differences between the groups (**P ≤ 0.001; ***P ≤ 0.0001). IgE levels at time points with the same superscript letter are significantly different (P ≤ 0.05) within each horse group. rCul n, recombinant Culicoides nubeculosus antigen; rCul o, recombinant Culicoides obsoletus antigen. sensitization in relation to onset of clinical signs, results of the IBHaffected horses one year before (T IBH -1) and one year after clinical onset (T IBH +1) were compared. The nonparametric Wilcoxon signed rank paired t-test was used to compare the sum of positive (i.e. above cut-off) IgE reactions of each individual horse against the Culicoides r-allergens (rCul n 2-n 10, rCul o 1-o 3) in the IBH group between the time points T IBH, T IBH À 1 and T IBH + 1, respectively. To avoid duplication, rCul n 1 was omitted for this analysis as it is the homologous allergen of rCul o 3. Both are antigen-5 like proteins and have an amino acid identity of 70%. The number of positive reactions at the three time points was also compared with the H control horses (Figure 2) . A Fisher's exact test was used to compare the number of IBHaffected and control horses with positive allergen-specific IgE results. This was performed for each of the single allergens in the 16 IBH-affected horses at T IBH and the H control horses (Figure 3) . A nonparametric Wilcoxon-Mann-Whitney U two sample t-test was performed to compare median IgE (Table S2 ) and median IgG subclasses (Table 2 ) levels against individual Culicoides r-allergens between IBH-affected horses at T IBH and H horses. The level of significance was set at P ≤ 0.05.
Results
Incidence of clinical signs of IBH In the end-point IBH group (n = 16), the median number of summers between importation and onset of clinical signs of IBH was two summers (range 1-4 summers). Four of the 16 end-point IBH horses developed clinical signs during the first summer after import, nearly half of the horses (seven of 16) after the second summer, three after the third and the remaining two horses after the fourth summer following import. Accordingly, within the IBH end-point group the cumulative frequencies of horses with IBH at each time point were 0% at T0, 25% at T1, 69% at T2, 88% at T3 and 100% at T4.
Time course of allergen-specific IgE levels in relation to clinical end-point Figure 1 shows that before first exposure to Culicoides spp. (T0), IgE levels to the Culicoides allergens were low and there were no differences in the Sum IgE(rCul n 1-10) or Sum IgE(rCul o 1-3) between the IBH and H groups. This was also true for the single allergens (Table S1 ). After the first summer (T1) there was no significant increase in IgE in either group. It was after the second summer (T2), when 11 out of the 16 IBH horses had developed clinical signs of IBH, that a significant increase was observed in the IBH but not in the H group (Figure 1) . Accordingly, there was a highly significant difference between the H and the IBH end-point group at T2 and T3. Within the IBH group, the significant increase in Sum IgE(Cul n) and Sum IgE(Cul o) was associated with the prevalence of clinical IBH at the different time points (Figure 1 ). This was also reflected in the results for the single allergens (Table S1 ). After the second summer, significant differences between both groups were seen for seven of the 13 tested r-allergens and the two extracts (Table S1 ).
Allergens sensitization in relation to clinical signs At T IBH -1, one summer before occurrence of clinical signs, the IBH group had IgE above cut-off to a median number of one allergen (Figure 2 ). This was not significantly different from the control group. There was a significant increase between T IBH -1 and T IBH (i.e. the summer of onset of clinical signs), with IgE levels above cut-off to a median number of 4.5 allergens in the IBH group. This also differed significantly from the control group. At T IBH , 12 of 16 IBH-affected horses exhibited positive IgE responses against two or more r-allergens. Only one IBH horse did not show any positive reactions to the tested r-allergens. The following summer (T IBH +1), nine of the 11 IBH horses that were assessed reacted against an equal or higher number of recombinant allergens than at T IBH . In contrast, only four healthy horses of 16 showed an IgE reaction towards one recombinant allergen. In order to determine which Culicoides allergens were of highest relevance at onset of the disease, the results at T IBH are presented for each single Culicoides allergen (percentage of positive reactions in Figure 3 and median values in Table S2 ). Nine of the ten r-Cul n allergens and NubTE bound allergen-specific IgE in at least three IBH horses (Figure 3a) . In contrast, a positive IgE response could be observed only for one H horse each for the allergens rCul n 2 and rCul n 6. For the allergens rCul n 4, n 5, n 8 and NubTE, the differences between the IBH and H groups were statistically significant. Only rCul n 4 and rCul n 8 bound IgE from ≥50% of the tested horses and thus seemed to be major allergens for IBH (Figure 3a ). All of the tested C. obsoletus allergens bound IgE in the sera from ≥50% of the IBH horses (Figure 3b ).
Time course of IgG subclasses responses
In order to assess whether the Culicoides-specific IgG subclass antibody response following import from Iceland to Europe differed between horses that developed IBH or remained healthy, a repeated measures ANOVA was performed. This was performed for the IgG subclasses, IgG1, IgG1/3, IgG4/7 and IgG5, as well as for IgE as comparison (Table 1 and illustrated for rCul o 3 in Figure 4 ).
For the IgG subclasses against the C. nubeculosus allergens (Table 1) , we found only few significant differences between the horse groups. At T2, IgG1 as well as IgG5 levels were significantly higher in the IBH group than in the controls, both for rCul n 4 and NubTE and there was a significant increase in IgG1 between T0 and T2 in the IBH-group for both rCul n 4 and NubTE. Furthermore, horses from the IBH group had significantly higher IgG1/3 against NubTE than the controls at all time points. Surprisingly, IgG4/7 levels were significantly higher in the controls at T0, both for rCul n 4 and NubTE.
The most striking differences for IgG subclasses were found with the rCul o allergens ( Table 1 ). The end-point IBH horses had significantly higher IgG5 levels against rCul o 1 and rCul o 3 (Figure 4 ) than the control horses at all time points and, surprisingly, already at T0. Significant differences between both groups of horses were also found for IgG1 and IgG1/3. Higher antibody levels were always observed in the IBH group compared to the controls, but the time points when these differences reached significance varied. As expected, there was a significant increase in IgE levels for each of the tested single allergens only in the IBH but not in the H end-point group. Significant differences between both horse groups were observed at T2 and T3. Finally, the same analysis was performed for IgE and IgG subclasses against equine influenza as control. No significant differences were observed between the groups for any antibody class at any time point, except for higher IgG1 at T0 in the IBH group compared to the control group. In contrast to the results obtained with the Culicoides allergens, there was no increase in IgE but a significant increase in IgG4/7 in both horse groups (Table 1) . Furthermore, significant increases in IgG1 and IgG1/3 levels were observed in both groups, whereas the increase in IgG5 only reached significance in the IBH-group.
Allergen-specific IgG subclasses in horses with clinical signs of IBH and H control horses
In order to further analyse differences in IgG subclass levels between healthy and IBH-affected horses, serum IgG subclass levels were compared between end-point IBH horses at time of onset of clinical signs (T IBH ) and H control horses matched for time since import (Table 2) . There was a significant difference between IBH-affected and nonaffected control horses in IgG1 levels against all tested allergens (rCul n 4, rCul o 1, rCul o 3, NubTE). Furthermore, IgG5 levels against rCul o 1, rCul o 3 and NubTE, but not rCul n 4, were significantly higher in the IBH-affected compared to the H control horses. No significant difference between the groups was found for IgG4/7. As expected, no significant differences in IgG subclass levels against equine influenza (used as a control) were found between the IBH and the H control group.
Discussion
Horses imported from Iceland, where Culicoides are absent, to Culicoides-rich environments, represent a unique model population to study the natural course of sensitization to new environmental allergens, because of the known time point of first Culicoides exposure and because of the high incidence of the disease in these horses. Previously, such studies were limited due to the lack of pure Culicoides allergens. 12 The expression of highly purified Culicoides r-allergens [2] [3] [4] [5] [6] has opened up new possibilities to investigate the natural sensitization process in this horse population.
At the time of import, before first exposure to Culicoides, allergen-specific IgE levels were absent or very low in the sera of the Icelandic horses. This is to be expected and confirms previous studies showing a low reactivity in the intradermal test by Icelandic horses living in Iceland. 18 Before exposure to Culicoides, there were no differences in allergen-specific IgE between end-point IBH and H groups (Figure 1) . A highly significant increase in IgE levels against Culicoides allergens was observed in the second summer after import in the IBH group, when the majority of horses had developed clinical signs of IBH, whereas IgE levels in the H group remained on a consistently low level throughout the study period. Induction of allergen-specific IgE production seems therefore to be linked to the occurrence of clinical signs. Although allergen-specific IgE closely reflects the clinical situation of the horses and may be useful for diagnostic purposes, it holds no predictive value as a biomarker for future development of IBH in horses. However, as antibody levels were only tested once a year in our study, we can only say that IgE does not increase in the Culicoides season preceding first occurrence of IBH signs. Monitoring the course of antibody levels more closely, with more frequent blood samplings during the IBH season would be helpful to more specifically pinpoint the exact timing of the increase in allergen-specific IgE.
Identification of primary sensitizing allergens and of the major allergens in the course of IBH-pathogenesis is a prerequisite for development of preventive and therapeutic vaccines, respectively. However, the present study revealed a complex sensitization pattern at the time of onset of clinical signs of IBH and confirms an earlier study using immunoblots with salivary gland extract. 12 Although sensitization against a maximum of one r-allergen was observed in the H control horses, IBH horses displayed positive IgE-levels against a median number of 4.5 allergens at time of first signs of IBH (Figure 2 ). Furthermore, a tendency for horses to show IgE reactivity against an increasing number of Culicoides allergens in the subsequent Culicoides seasons after first onset of IBH was observed in the IBH group. We suspect that this increase would be even more distinct if no preventive measures against Culicoides exposure, such as use of blankets, had been taken once IBH diagnosis was established. Additionally, the r-allergens that IBH horses were sensitized to varied widely between individual horses. Nevertheless, some r-allergens, notably rCul o 1 (a Kunitz-protease inhibitor), rCul o 2 (a D7-related protein), rCul o 3 (an antigen-5 like protein), as well as the C. nubeculosus allergens rCul n 4 and rCul n 8, elicited IgE responses in ≥50% of IBH horses and could therefore be classified as major allergens (Figure 3) . The other tested r-allergens bound IgE antibodies from a smaller number of horses. To further elucidate the role of individual r-allergens as potential primary sensitizing allergens, studies using a larger number of horses and a complete panel of all known Culicoides allergens is required.
A further aim of our study was to investigate IgG subclasses in IBH, using two of the most relevant C. obsoletus allergens, rCul o 1 and rCul o 3, as well as one of the most relevant C. nubeculosus allergens, rCul n 4. At time of onset of clinical signs, the IBH group had significantly higher IgG1 and IgG5 levels against all tested allergens than the control group. This is in accordance with some studies in the human allergy field, showing that IgG responses are more frequent and stronger in individuals with current IgE sensitization 19 and that some IgG subclasses (i.e. human IgG4) are increased in atopic compared to nonatopic individuals. 20 However, the IgG response to allergenic molecules is very complex and highly dependent on the route of allergen exposure. 21 Our data strongly suggest that IgG5 is the subclass associated with allergy in horses. Previous studies had shown that IgG3 and IgG5 responses are mainly induced by extracellular pathogens; 22, 23 whereas IgG4, IgG7 and Results are displayed as log OD 405 . T0-T3 correspond to the yearly blood samples, with T0 representing the blood sample collected before exposure to Culicoides and T1-T3 representing the blood samples collected at the end of each subsequent summer. This figure illustrates the results of the repeated measures ANOVA, also described in Table 1 . Asterisks indicate significant differences between the groups (**P ≤ 0.001. ***P ≤ 0.0001). Time points with the same superscript letter are significantly different (P ≤ 0.05) within each horse group.
probably IgG1 protect against various intracellular infections. 17, 24, 25 Our data indicate that IgG1 but not IgG4/7 levels increase following exposure to Culicoides, mainly in the IBH group. IgG5 also increased over time but this increase only reached statistical significance for Bac-rCul o 3 in the IBH group (Table 1) . Horses from the IBH group thus had usually significantly higher allergen-specific IgG1 and IgG5 than the H group. Furthermore, these results using Culicoides r-allergens confirm previous studies with immunoblots of Culicoides salivary gland extract where horses with IBH had IgE as well as IgGa (corresponding to IgG1) and IgG(T) (corresponding to IgG3 & 5) against a higher number of protein bands than healthy controls, whereas no significant difference was seen for IgG(b), which corresponds to IgG4/7. 12 On the other hand, the present study shows that vaccination with equine influenza resulted in a strong increase in IgG1 and IgG4/7 against equine influenza and a weak increase in equine influenza-specific IgG5 in the IBH group, whereas no IgE was induced. No differences between the IBH and H horse groups was found except for higher IgG1 levels at T0 in the IBH group. This is due to the fact that pre-Culicoides exposure blood samples in a few of these horses were taken in the winter months and several weeks after import to Europe and when they had already received the first vaccination against equine influenza.
Most surprisingly, our study revealed that horses that developed IBH after import to Europe already had significantly higher IgG5 levels against rCul o 1 and rCul o 3 before Culicoides exposure. A previous study had demonstrated that the antigen 5-like allergen from Simulium vittatum (S. vittatum) and C. nubeculosus is crossreactive. 3 Furthermore, a Kunitz Protease Inhibitor from S. vittatum had been identified as an IgE-binding protein, binding IgE from sera of IBH-affected horses significantly more frequently than from healthy controls. 26 High IgG5 levels to rCul o 1 and rCul o 3 in Icelandic horses before exposure to Culicoides could thus be due to cross-reactivity between Simulium and Culicoides salivary proteins, as S. vittatum are present in Iceland. 27 Further studies are needed to elucidate the role of rCul o 1-and rCul o 3-specific IgG5 antibodies in IBH and, in particular, why IgG5 but not IgE antibodies specific for these proteins can be detected in the sera before exposure to Culicoides.
In conclusion, the present study shows that first exposure of adult Icelandic horses to Culicoides induces an individual IgE response pattern and that the increase in serum IgE levels to Culicoides allergens is concurrent with the initial onset of clinical signs of IBH. Allergen-specific serum IgE can thus be used to confirm the clinical diagnosis but not as a predictor for IBH. Furthermore, IgG5 levels to the C. obsoletus allergens rCul o 1 and rCul o 3 were already increased year(s) before the first clinical signs of IBH were noted. Further studies are needed to test whether increased allergen-specific IgG5 levels may have a predictive value for IBH.
